Related Experiment Video
Updated: Aug 18, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
Rifaximin in the treatment of infectious diarrhea
Charles D Ericsson1, Herbert L DuPont
1Department of Internal Medicine and Division of Infectious Diseases, University of Texas Houston Medical School, Houston, TX 77030, USA. Charles.D.Ericsson@uth.tmc.edu
Abstract:
Rifaximin matches the criteria for an ideal agent for the treatment of infectious diarrhea. It has excellent activity against a broad range of enteropathogens. It is nonabsorbable, which may help explain its excellent side effect profile and lack of emergence of resistance because of high stool levels that are not likely to reach subinhibitory levels before the target Gram-negative bacilli are killed. It has shown excellent efficacy in numerous clinical trials of bacterial diarrhea. Because of the lack of systemic absorption and minimal adverse reactions, rifaximin should be useful in treating hosts such as pregnant women in whom the currently favored fluoroquinolones are contraindicated. Uses limited to enteric indications and its inherently low propensity to induce sustainable resistance among Gram-negative flora favor the sustained usefulness of rifaximin in the treatment of enteric infectious syndromes.
Insights
Rifaximin is an ideal treatment for infectious diarrhea due to its broad-spectrum activity and non-absorbable nature. This profile ensures efficacy and safety, minimizing resistance development for bacterial diarrhea treatment.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Infectious diarrhea poses a significant health challenge, necessitating effective and safe antimicrobial agents.
- Current treatments like fluoroquinolones have limitations, especially in specific patient populations.
Purpose of the Study:
- To evaluate rifaximin as an ideal agent for treating infectious diarrhea.
- To assess its efficacy, safety, and resistance profile against enteropathogens.
Main Methods:
- Review of clinical trials and pharmacological data on rifaximin.
- Analysis of rifaximin's activity against a broad range of enteropathogens.
- Assessment of its non-absorbable properties and impact on resistance.
Main Results:
- Rifaximin demonstrates excellent activity against a wide spectrum of enteropathogens.
- Its non-absorbable nature leads to a favorable side effect profile and low resistance emergence.
- Clinical trials confirm high efficacy in treating bacterial diarrhea.
Conclusions:
- Rifaximin is a highly effective and safe option for infectious diarrhea, particularly for patients where fluoroquinolones are contraindicated.
- Its targeted action and low resistance potential support its sustained utility in treating enteric infections.
Related Concept Videos
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inhibitors of Bacterial DNA Synthesis
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
